Larson Financial Group LLC Has $252,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Larson Financial Group LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 73.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 609 shares of the company’s stock after selling 1,645 shares during the period. Larson Financial Group LLC’s holdings in IDEXX Laboratories were worth $252,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of IDXX. Concurrent Investment Advisors LLC raised its holdings in IDEXX Laboratories by 4.7% during the third quarter. Concurrent Investment Advisors LLC now owns 630 shares of the company’s stock worth $318,000 after acquiring an additional 28 shares in the last quarter. CWA Asset Management Group LLC bought a new stake in IDEXX Laboratories in the third quarter valued at approximately $308,000. Assetmark Inc. raised its stake in IDEXX Laboratories by 4.1% in the third quarter. Assetmark Inc. now owns 18,427 shares of the company’s stock valued at $9,310,000 after buying an additional 723 shares during the period. Sigma Planning Corp raised its stake in IDEXX Laboratories by 12.6% in the third quarter. Sigma Planning Corp now owns 1,892 shares of the company’s stock valued at $956,000 after buying an additional 212 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in IDEXX Laboratories in the third quarter valued at approximately $37,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Finally, Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $533.75.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Up 1.5 %

Shares of NASDAQ:IDXX opened at $436.48 on Tuesday. The company has a market capitalization of $35.50 billion, a P/E ratio of 40.91, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $562.25. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business’s 50 day simple moving average is $437.84 and its 200 day simple moving average is $448.70.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.